Oocyte in vitro maturation in normo-ovulatory women

Fadini, Rubens; Renzini, Mario Mignini; Canto, Mariabeatrice Dal; Epis, A.; Crippa, Marilena; Caliari, Ilaria; Brigante, Claudio; Coticchio, Giovanni

doi:10.1016/j.fertnstert.2013.01.138

Cited by 55 publications

(43 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, animal studies and studies of children born after IVM are quite reassuring so far and show no evidence of an increased risk of congenital malformations, abnormal neonatal growth, or imprinting syndromes. 20,21 Further study would be done to ascertain the implantation and pregnancy potential of the resulting embryos.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Blastocyst and Sage Media for In Vitro Maturation of Human Immature Oocytes

2015

View full text Add to dashboard Cite

In vitro maturation (IVM) of human oocytes is an attractive alternative to conventional assisted reproductive technology (ART) treatment, as it involves no or minimal ovarian stimulation. Currently, commercialized media specifically designed for IVM are often used. These media are expensive, have limited shelf life, and must be ordered in advance. If standard culture media can be used in place of the specialized IVM media, it would simplify management and make IVM more feasible and more widely employed in ART centers around the world, especially in developing countries where resources are scarce. This study was, therefore, conducted to test the hypothesis that blastocyst medium was as good as commercial IVM medium to support maturation and developmental competence of human immature oocytes as previously shown in the mouse system. Immature oocytes were obtained by needle aspiration from 89 pregnant women during cesarean deliveries between April 2012 and February 2013. Sibling oocytes were allocated to Sage IVM media (512 oocytes) or blastocyst medium (520 oocytes) and assessed for maturation 36 hours later. Mature oocytes were inseminated by intracytoplasmic sperm injection and cultured up to 144 hours. There was no difference in maturation rate (65.0% vs 68.7%; P ¼ .218) or fertilization rate (66.9% vs 66.4%; P ¼ .872) of oocytes matured in vitro in both media. There was also no difference in the formation of good-quality blastocysts (46.6% vs 45.9%; P ¼ .889) in the 2 groups. Further study should be done to ascertain implantation and pregnancy potential of these embryos.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of Blastocyst and Sage Media for In Vitro Maturation of Human Immature Oocytes

2015

View full text Add to dashboard Cite

show abstract

“…Por este motivo, la MIV está principalmente dirigida a pacientes con alto riesgo de desarrollar SHO, como el SOP (6)(7)(8)(9)(10)(11)(12). Las pacientes con ciclos menstruales regulares también se benefician (13,14), como pacientes oncológicas que desean preservar su fertilidad (15). Basados en la teoría de Baerwald y cols, quienes sugieren que existiría más de una ola de crecimiento folicular durante el ciclo menstrual y que el crecimiento de folículos antrales podría iniciarse y continuarse en cualquier momento del ciclo menstrual (16), Demirtas y cols y Maman y cols demostraron que ovocitos inmaduros aspirados durante la fase lútea eran capaces de madurar in vitro (17,18).…”

Section: Discussionunclassified

Maduración in vitro de ovocitos humanos: una opción para preservar la fertilidad de las mujeres. Reporte del primer caso realizado en Chile

Ortega-Hrepich¹,

M²,

Arguello³

et al. 2014

Rev. chil. obstet. ginecol.

View full text Add to dashboard Cite

“…Despite this, IVM is not widespread for a few reasons: PCOS women only represent 5-10% of ART patients, normo-ovulatory women do not typically have enough antral follicles required for early oocyte retrieval in IVM, and lastly, due to in vitro matured oocytes having a reduced developmental potential compared to those matured in vivo [10,78,81].…”

Section: Progress Of Ivfmentioning

confidence: 99%

Assessment of the Field of Assisted Reproductive Technology: Improvements and the Future of Human In Vitro Fertilization

Brown¹

2015

JFIV Reprod Med Genet

View full text Add to dashboard Cite

In vitro fertilization (IVF), a form of assisted reproductive technology, has expanded since its introduction in the 1970's to enable patients with prolonged infertility and/or clinical complications to produce biological offspring. This review analyzes the topics of controversy surrounding IVF, weighing evidence concerning contemporary fertility techniques that aim to advance the field of IVF. A comparison of single embryo transfer to double embryo transfer, in the context of economic expenditure and the likelihood of multiple pregnancy, provides support for electing the former. An ethically controversial topic is preimplantation genetic screening, a technology with the potential to reduce the incidence of genetic abnormalities, thereby increasing rates of healthy pregnancies. Lastly, the integration of in vitro maturation (IVM) can allow for a more diverse patient population to benefit from IVF treatment, while simultaneously avoiding several of the associated disadvantages. The future of IVF rests on continued research, and the resulting widespread integration of increasingly effective methods.

show abstract

Oocyte in vitro maturation in normo-ovulatory women

Cited by 55 publications

References 36 publications

Comparison of Blastocyst and Sage Media for In Vitro Maturation of Human Immature Oocytes

Comparison of Blastocyst and Sage Media for In Vitro Maturation of Human Immature Oocytes

Maduración in vitro de ovocitos humanos: una opción para preservar la fertilidad de las mujeres. Reporte del primer caso realizado en Chile

Assessment of the Field of Assisted Reproductive Technology: Improvements and the Future of Human In Vitro Fertilization

Contact Info

Product

Resources

About